glp 1 conference ASAM eLearning: Semaglutide Circus: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Treat Addiction Policymakers and health care providers
Description
Per Member Per Month (PMPM) Cost Pressures The financial challenges tied to GLP-1s are starkly illustrated by the rise in per member per month (PMPM) costs
Insufficient sample size to report among uninsured adults who have ever taken these drugs
Severe or persistent injection site reactions leading to treatment discontinuation are uncommon in clinical trials
Allulose only came to market in 2015 and has been approved for use in the US, Singapore, the Philippines and several Latin America countries, including Chile, Colombia, Ecuador, Peru and Mexico
Journal of Comparative Neurology, 403(2), 261280
